Interleukin-2 (IL-2) has been shown to suppress immune pathologies by preferentially expanding regulatory T cells (T). However, this therapy has been limited by off-target complications due to pathogenic cell expansion. Recent efforts have been focused on developing a more selective IL-2. It is well documented that certain anti-mouse IL-2 antibodies induce conformational changes that result in selective targeting of T. We report the generation of a fully human anti-IL-2 antibody, F5111.2, that stabilizes IL-2 in a conformation that results in the preferential STAT5 phosphorylation of T in vitro and selective expansion of T in vivo. When complexed with human IL-2, F5111.2 induced remission of type 1 diabetes in the NOD mouse model, reduced disease severity in a model of experimental autoimmune encephalomyelitis and protected mice against xenogeneic graft-versus-host disease. These results suggest that IL-2-F5111.2 may provide an immunotherapy to treat autoimmune diseases and graft-versus-host disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6398608 | PMC |
| http://dx.doi.org/10.1038/s41591-018-0070-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
An antibody against human interleukin-2 showing minimal binding to neonatal Fc receptor: Potent anti-tumor activity and reduced systemic toxicity in mice.
Eur J Pharmacol
January 2025
School of Life Science and Biopharmaceuticals, Shenyang Pharmaceutical University, 103 Culture Road, Shenhe District, Shenyang, Liaoning, 110016, China; Shenyang Sunshine Pharmaceuticals Co., Ltd, Economic and Technological Development Zone, Shenyang, Liaoning, 110027, China.
The anti-tumor efficacy of immune checkpoint inhibitors can be enhanced by combining them with interleukin-2 (IL-2), which promotes the clonal expansion of antigen-activated CD8 T cells and natural killer cells. However, IL-2 can simultaneously bind to endothelial cells and regulatory T cells to induce adverse and immunosuppressive effects. Such off-target binding can be inhibited by co-administering IL-2 with anti-IL-2 antibodies, but these antibodies can interact with neonatal Fc receptor to protect the IL-2 from lysosomal degradation, leading to substantial toxicity.
View Article and Find Full Text PDFWiskott-Aldrich syndrome protein maintains regulatory T cell tolerance by modulating their surface IL-2 receptor levels.
J Autoimmun
December 2024
National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Children's Hospital of Chongqing Medical University, Chongqing, China; Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity, Children's Hospital of Chongqing Medical University, Chongqing, China; Division of Rheumatology and Immunology, Children's Hospital of Chongqing Medical University, Chongqing, 400014, China. Electronic address:
Wiskott-Aldrich syndrome (WAS) is an X-linked immunodeficiency condition caused by ablation of functional WAS protein (WASP) expression, and associated with susceptibility to infections, eczema, and autoimmunity. Regulatory T cell (Treg) defects are an important cause of autoimmunity in WAS. Currently, the mechanisms underlying cytoskeleton involvement in Treg-regulated autoimmunity remain unclear, and WAS is an excellent model for investigation of this question.
View Article and Find Full Text PDFEngineered cytokine/antibody fusion proteins improve IL-2 delivery to pro-inflammatory cells and promote antitumor activity.
JCI Insight
September 2024
Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Progress in cytokine engineering is driving therapeutic translation by overcoming these proteins' limitations as drugs. The IL-2 cytokine is a promising immune stimulant for cancer treatment but is limited by its concurrent activation of both pro-inflammatory immune effector cells and antiinflammatory regulatory T cells, toxicity at high doses, and short serum half-life. One approach to improve the selectivity, safety, and longevity of IL-2 is complexing with anti-IL-2 antibodies that bias the cytokine toward immune effector cell activation.
View Article and Find Full Text PDFArticle Synopsis
- ANV419 Development
- : ANV419 is a novel fusion protein that combines IL-2 with an antibody to specifically activate certain immune cells while minimizing side effects commonly seen with traditional IL-2, like aldesleukin.
- Selective Immune Response
- : The fusion protein preferentially boosts the population of CD8 T cells and natural killer (NK) cells, demonstrating strong anti-tumor effects and improved tolerance levels in clinical testing, especially in mouse models.
- Clinical Potential
- : With a favorable half-life and manageable dosing, ANV419 is being tested in Phase 1/2 clinical trials for treating various cancers, potentially offering patients a safer and more effective alternative to existing IL-
Switching patterns of biological drugs in patients with psoriasis and psoriatic arthritis: insight from the VALORE database network.
Expert Opin Biol Ther
May 2024
Department of Diagnostics and Public Health, University of Verona, Verona, Italy.
Background: Switch patterns among different biologics and from originators to biosimilars (and vice versa) can be complex in patients with psoriasis (PsO) and psoriatic arthritis (PsA).
Objective: The aim of this study was to describe switching patterns of biological drugs in PsO/PsA patients and to explore predictors of multiple switches and switch-back.
Research Design And Methods: A large-scale retrospective cohort study was conducted using the Italian VALORE database.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!